Latest Articles
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - The AI Journal
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer The AI Journal
Published: Oct. 20, 2025, 9:33 p.m.
Endometrial Ablation as a Safe Treatment for Adenomyosis-Related Abnormal Uterine Bleeding in Women with Cerebral Infarction: A Case Report - Frontiers
Endometrial Ablation as a Safe Treatment for Adenomyosis-Related Abnormal Uterine Bleeding in Women with Cerebral Infarction: A Case Report Frontiers
Published: Oct. 20, 2025, 9 p.m.
Faeth Therapeutics: $25 Million Raised To Advance PIKTOR Phase 2 Trial Following 80% Response Rate In Endometrial Cancer - Pulse 2.0
Faeth Therapeutics: $25 Million Raised To Advance PIKTOR Phase 2 Trial Following 80% Response Rate In Endometrial Cancer Pulse 2.0
Published: Oct. 20, 2025, 3:54 p.m.
Faeth Therapeutics Raises $25 Million, Reports Phase 2 Results in Ovarian and Endometrial Cancer - Femtech Insider
Faeth Therapeutics Raises $25 Million, Reports Phase 2 Results in Ovarian and Endometrial Cancer Femtech Insider
Published: Oct. 20, 2025, 2:27 p.m.
ESMO 2025: MSD and Eisai’s endometrial cancer combo shows five-year durability - Yahoo
ESMO 2025: MSD and Eisai’s endometrial cancer combo shows five-year durability Yahoo
Published: Oct. 20, 2025, 2:07 p.m.
ESMO 2025: MSD and Eisai’s endometrial cancer combo shows five-year durability - Clinical Trials Arena
ESMO 2025: MSD and Eisai’s endometrial cancer combo shows five-year durability Clinical Trials Arena
Published: Oct. 20, 2025, 1:12 p.m.
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - Business Wire
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer Business Wire
Published: Oct. 20, 2025, noon
Shifted assembly and function of mSWI/SNF family subcomplexes underlie targetable dependencies in dedifferentiated endometrial carcinomas - Nature
Shifted assembly and function of mSWI/SNF family subcomplexes underlie targetable dependencies in dedifferentiated endometrial carcinomas Nature
Published: Oct. 20, 2025, 9:19 a.m.
Advances in Endometrial Cancer Biomarkers via Multi-Omics - Bioengineer.org
Advances in Endometrial Cancer Biomarkers via Multi-Omics Bioengineer.org
Published: Oct. 20, 2025, 6:54 a.m.
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer - BioSpace
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer BioSpace
Published: Oct. 20, 2025, 4:42 a.m.
Link copied to clipboard!